AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04234867
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 5 days
Trial: NCT05924594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.
Trial: NCT06393413
Drug: Jiedu Yizhi Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation after 24 weeks of drug treatment
Trial: NCT05813964
Drug: TDF/FTC 300mg/200mg fixed-dose combination tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Event-driven dosing regimen
Trial: NCT05813964
Drug: TAF/FTC 25mg/200mg fixed-dose combination tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Event-driven dosing regimen.
Trial: NCT04574869
Drug: RLS-0071 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose IV infusion of 10 mg/kg RLS-0071
Trial: NCT05298163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule matching the active drug will be given per day for 6 months, starting at the day of the time when inclusion criteria have been met
Trial: NCT05815862
Drug: AL2846 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL2846 is a multi-target tyrosine kinase inhibitor.
Trial: NCT05314998
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1660mg/m2/day in two divided doses administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles i.e. 24 weeks
Trial: NCT05432284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (ambient air)
Trial: NCT05432284
Drug: Beta-Myrcene
RxNorm normalized name: myrcene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure beta-myrcene vapor
Trial: NCT05539248
Drug: CAN106 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction and maintenance dosing for cohort 1:~12 mg/kg on Day 1, 16 mg/kg on Day 8, and 20 mg/kg on Day 15 and every 4 weeks thereafter;
Trial: NCT05539248
Drug: CAN106 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction and maintenance dosing for cohort 2:~30 mg/kg on Day 1, and 40mg/kg on Day 8 and every 4 weeks thereafter；
Trial: NCT05539248
Drug: CAN106 80 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction and maintenance dosing for cohort 3:~60 mg/kg on day 1, and 80 mg/kg on day 15 and every 8 weeks thereafter.
Trial: NCT06556186
Drug: Bromocriptin 2.5mg, 2-3 times a day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptin 2.5mg, 2-3 times a day
Trial: NCT05053009
Drug: Brufen Retard
RxNorm normalized name: Brufen Retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg tablet of Brufen Retard will be adminstered orally one hour before local anesthesia
Trial: NCT04713371
Drug: Keytruda Injectable Product
RxNorm normalized name: Keytruda Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected.
Trial: NCT04713371
Drug: Yervoy Injectable Product
RxNorm normalized name: Yervoy Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected.
Trial: NCT05515042
Drug: Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As included in arm/group descriptions
Trial: NCT04688268
Drug: deep neuromuscular blockade
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Train of Four=0/4, Post tetanic count 1-2
Trial: NCT05005065
Drug: IN-C005 X mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT05005065
Drug: IN-A001 Y mg
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05005065
Drug: IN-C005 Y mg
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT04761562
Drug: Platelet- and extracellular vesicle-rich plasma
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRP will initially be applied to the gelatine sponge without prior exogenous activation, which will first be inserted into the middle ear cavity to support the reconstructed tympanic membrane. The remainder of the PVRP will then be exogenously activated with calcium chloride. Gel rich with platelets and extracellular vesicles will be created and applied on top of the reconstructed tympanic membrane. Finally, the external auditory canal will be filled with pieces of gelatine sponge soaked with PVRP.
Trial: NCT06258980
Drug: Proph7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic recombinant FVII for heavily menorrhagic adolescent Glanzmanns Thrombaesthenia females
Trial: NCT04704739
Drug: GLPG1205 film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of GLPG1205
Trial: NCT04704739
Drug: GLPG1205 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of GLPG1205 as solid formulation
Trial: NCT06632106
Drug: Tyrosine kinase inhibitor (TKIs)
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab
Trial: NCT04991662
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion of Norepinephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
Trial: NCT05502211
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: induction of anaesthesia using fentanyl
Trial: NCT04911894
Drug: IBI321
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
Trial: NCT06077019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants inhale placebo daily
Trial: NCT05857358
Drug: Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF)
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous uncultured (AD-SVF) will be isolated by digestion and centrifugation of adipose tissue from lipoaspiration.~Then, AD-SVF will be injected in 6 sites :~* 2 for the accessory labial glands (0.5mL in the upper lip and 0.5mL in the lower lip)~* 2 for the sublingual glands (0.5mL for each gland)~* 2 for the inner face of cheeks (0.5mL for each side)~The volume of injection will be of 3 mL containing 30 millions of AD-SVF viable nucleated cells for the total safety dose.
Trial: NCT05899140
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin will be administered at a dose of 450 mg TDS (oral) or 10 mg/kg/dose QID iv (maximum 600mg QID iv) for a maximum of 7 days
Trial: NCT04766463
Drug: SHR8554 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR8554 Injection; high dose
Trial: NCT04766463
Drug: SHR8554 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR8554 Injection; low dose
Trial: NCT04766463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Solution
Trial: NCT05338034
Drug: HPG1860
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.
Trial: NCT05338034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT04830579
Drug: Etoricoxib film-coated tablet 120 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 120 mg of etoricoxib.
Trial: NCT04830579
Drug: Arcoxia® film-coated tablet 120 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arcoxia® is manufactured by Frosst Iberica SA, Spain. Each tablet contains 120 mg of etoricoxib.
Trial: NCT06462183
Drug: RGT-61159
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral MYB inhibitor
Trial: NCT05347199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two doses, orally
Trial: NCT04258410
Drug: Placebo oral soft chew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo identical to experimental drug contained in soft chew
Trial: NCT05998525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients who meet the inclusion criteria and after catheterization will be randomized to receive a placebo pill 24 hours and upon discharge treatment will continue for 12 months
Trial: NCT04258826
Drug: LY3154207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3154207 administered orally.
Trial: NCT04258826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally.
Trial: NCT06129643
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
Trial: NCT04979988
Drug: Lortlatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as provided in real world practice
Trial: NCT03534102
Drug: Improved Opioid-Tapering Instructions
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied to first and second experimental groups in the form of discharge instructions and directions from nursing staff.
Trial: NCT05850091
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacotherapy for reduction in LDL cholesterol level
Trial: NCT05850091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule with sugar pill that mimics active study drugs
Trial: NCT05819541
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
Trial: NCT05328414
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal fast dissolving film to be applied intranasal. it contains 0.005 mg Presdnisolone
Trial: NCT05604885
Drug: AP1189, 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP1189 tablets for oral use
Trial: NCT05604885
Drug: AP1189, 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP1189 tablets for oral use
Trial: NCT05604885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets for oral use
Trial: NCT05288855
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsule
Trial: NCT04771481
Drug: Normal Saline 10 mL Injection
RxNorm normalized name: normal saline 10 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
Trial: NCT06421688
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After participants underwent induction of anesthesia, Ascorbic acid (Vitamin C Injection) was administered at a dosage of 50 mg/kg, diluted to 50 ml using saline, with a total amount not exceeding 4 g; pumping was performed using a micro pump at a rate of 25 ml/h.
Trial: NCT05171673
Drug: Licart™ (diclofenac epolamine) topical system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
Trial: NCT05218733
Drug: General anesthesia using intravenous fentanyl (1µgm/kg)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive general anesthesia using intravenous fentanyl (1µgm/kg)
Trial: NCT06627335
Drug: TCS
RxNorm normalized name: TCS-OX2-29
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid
Trial: NCT04862741
Drug: NX-13 250mg IR
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
Trial: NCT04862741
Drug: NX-13 500mg MR
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
Trial: NCT06102525
Drug: RZ-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
Trial: NCT05292638
Drug: CKDB-501A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection CKDB-501A
Trial: NCT05292638
Drug: Botox®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection Botox®
Trial: NCT06727435
Drug: non-sedation strategy
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients eligible for this study will undergo non-sedation strategy, which continuous analgesia without sedation is performed with remifentanil. The remifentanil will be titrated (from 0.1µg/kg/min to 0.2ug/kg/min) every 10-15 minutes to achieve the goal for sedation (RASS score maintaining -2 to + 1). The patients in the non-sedation trial do not receive any sedatives but could receive bolus doses (2.5 or 5mg) of morphine for analgesia.
Trial: NCT05981534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be used for 6 months
Trial: NCT05598151
Drug: HM97662
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the safety, tolerability, preliminary anti-tumor efficacy, PK and PD of HM97662 in solid tumors
Trial: NCT05586230
Drug: Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.
Trial: NCT05387837
Drug: D-4517.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
Trial: NCT06097026
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer nitric oxide upon arrival from cardiac surgery and assess cardiac and pulmonary function afterwards.
Trial: NCT05882812
Drug: 2.5% Diclofenac Patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
Trial: NCT05265208
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will given at 1250mg/m², 2 times a day with an interval of about 12 hours between two intakes, 2 weeks on, 1 week off, for 4 pre-surgery cycles.
Trial: NCT04853355
Drug: Spironolactone 50 mg
RxNorm normalized name: spironolactone 50 MG
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add Spironolactone 50 mg to previous regimen
Trial: NCT05282069
Drug: DA-8010 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive placebo to match DA-8010 orally once a day.
Trial: NCT05282069
Drug: DA-8010 2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive DA-8010 2.5mg orally once a day.
Trial: NCT05361824
Drug: Ketorolac Injection
RxNorm normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage form: intravenous dosage: 30mg frequency: 8 hours apart (TDS) duration: for 48 hours post operatively
Trial: NCT06437262
Drug: 0.20% CHX gel on saliva
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.
Trial: NCT06437262
Drug: 0.20% CHX and Cymenol gel on saliva
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.
Trial: NCT06437262
Drug: 0.20% CHX gel on oral biofilm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
Trial: NCT06437262
Drug: 0.20% CHX and Cymenol gel on oral biofilm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
Trial: NCT06081686
Drug: Phase II:[177Lu]Lu-XT033 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received \[177Lu\]Lu-XT033 Injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
Trial: NCT05905913
Drug: ANT3310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANT3310 will be infused over 3 hours
Trial: NCT05905913
Drug: ANT3310-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANT3310-placebo will be infused over 3 hours
Trial: NCT05905913
Drug: ANT3310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANT3310 will be infused over 3 hours every 8 hours
Trial: NCT05905913
Drug: ANT3310-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANT3310-placebo will be infused over 3 hours every 8 hours
Trial: NCT05905913
Drug: ANT3310-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANT3310-placebo will be infused over 3 hours as a single dose as part of the drug drug interaction study, then every 8 hours as part of the repeat doses study.
Trial: NCT05905913
Drug: ANT3310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANT3310 will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
Trial: NCT05266612
Drug: VG2025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. 1.0×108PFU Day 1 and 15~2. 2.0×108PFU Day 1 and 15~3. 3.0×108PFU Day 1 and 15~4. 4.0×108PFU Day 1 and 15
Trial: NCT05263960
Drug: CM350_group 5b
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 135ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05263960
Drug: CM350_group 6b
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 270ug on C1D8, 270ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05263960
Drug: CM350_group 7
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 405ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05263960
Drug: CM350_group 8
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 405ug of CM350 on the first day of first cycle (C1D1), 405ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.